50 related articles for article (PubMed ID: 9590231)
1. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.
Smith JA; Tang Q; Bluestone JA
J Immunol; 1998 May; 160(10):4841-9. PubMed ID: 9590231
[TBL] [Abstract][Full Text] [Related]
2. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.
Smith JA; Tso JY; Clark MR; Cole MS; Bluestone JA
J Exp Med; 1997 Apr; 185(8):1413-22. PubMed ID: 9126922
[TBL] [Abstract][Full Text] [Related]
3. Non FcR-binding murine antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation.
Meijer RT; Yong SL; ten Berge IJ; van Lier RA; Schellekens PT
Clin Exp Immunol; 2001 Mar; 123(3):511-9. PubMed ID: 11298141
[TBL] [Abstract][Full Text] [Related]
4. Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment.
Fotino C; Molano RD; Ben Nasr M; Umland O; Fraker CA; Ulissi U; Balasubramanian HB; Lunati ME; Usuelli V; Seelam AJ; Khalefa SA; La Sala C; Gimeno J; Mendez AJ; Ricordi C; Bayer AL; Fiorina P; Pileggi A
Diabetes; 2023 Nov; 72(11):1641-1651. PubMed ID: 37625134
[TBL] [Abstract][Full Text] [Related]
5. A novel trivalent non-Fc anti-CD3 Collabody preferentially induces Th1 cell apoptosis
Huang CC; Sung HH; Li HC; Miaw SC; Kung JT; Chou MY; Wu-Hsieh BA
Front Immunol; 2023; 14():1201853. PubMed ID: 37600814
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus.
Morita M; Mizui M; Masuyama S; Tsokos GC; Isaka Y
Front Immunol; 2022; 13():855812. PubMed ID: 35419004
[TBL] [Abstract][Full Text] [Related]
7. Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes.
Benson RA; Garcon F; Recino A; Ferdinand JR; Clatworthy MR; Waldmann H; Brewer JM; Okkenhaug K; Cooke A; Garside P; Wållberg M
Front Immunol; 2018; 9():1006. PubMed ID: 29867981
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity.
Wallberg M; Recino A; Phillips J; Howie D; Vienne M; Paluch C; Azuma M; Wong FS; Waldmann H; Cooke A
Immunology; 2017 Jun; 151(2):248-260. PubMed ID: 28211040
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.
Spitz C; Winkels H; Bürger C; Weber C; Lutgens E; Hansson GK; Gerdes N
Cell Mol Life Sci; 2016 Mar; 73(5):901-22. PubMed ID: 26518635
[TBL] [Abstract][Full Text] [Related]
10. Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.
He W; Racine JJ; Johnston HF; Li X; Li N; Cassady K; Liu C; Deng R; Martin P; Forman S; Zeng D
Biol Blood Marrow Transplant; 2014 Jul; 20(7):920-8. PubMed ID: 24691220
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte subset characterization in patients with early clinical presentation of coronary heart disease.
Brunetti ND; D'Antuono C; Rana M; D'Arienzo G; De Gennaro L; Di Biase M
J Thromb Thrombolysis; 2012 Nov; 34(4):475-82. PubMed ID: 22903683
[TBL] [Abstract][Full Text] [Related]
12. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.
Jeker LT; Bour-Jordan H; Bluestone JA
Cold Spring Harb Perspect Med; 2012 Mar; 2(3):a007807. PubMed ID: 22393537
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.
Penaranda C; Tang Q; Bluestone JA
J Immunol; 2011 Aug; 187(4):2015-22. PubMed ID: 21742976
[TBL] [Abstract][Full Text] [Related]
14. Challenges in the pursuit of immune tolerance.
Nepom GT; St Clair EW; Turka LA
Immunol Rev; 2011 May; 241(1):49-62. PubMed ID: 21488889
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.
Li J; Zhou B; Shentu J; Du L; Tan M; Hou S; Qian W; Li B; Zhang D; Dai J; Wang H; Zhang X; Chen J; Guo Y
MAbs; 2010; 2(4):449-56. PubMed ID: 20519962
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of type 1 diabetes: where are we and where should we be going?
Luo X; Herold KC; Miller SD
Immunity; 2010 Apr; 32(4):488-99. PubMed ID: 20412759
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis of thyroid eye disease: emerging paradigms.
Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS
Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.
Podojil JR; Miller SD
Immunol Rev; 2009 May; 229(1):337-55. PubMed ID: 19426232
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease.
Podojil JR; Turley DM; Miller SD
Adv Exp Med Biol; 2008; 640():234-51. PubMed ID: 19065796
[TBL] [Abstract][Full Text] [Related]
20. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.
Ochi H; Abraham M; Ishikawa H; Frenkel D; Yang K; Basso A; Wu H; Chen ML; Gandhi R; Miller A; Maron R; Weiner HL
J Neurol Sci; 2008 Nov; 274(1-2):9-12. PubMed ID: 18804221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
